Table 2.

Replication of SPARTAN hazard ratios matched for PROSPER characteristics

	Originala	MAIC weighteda,b
	HR (95% CI), p value	HR (95% CI), p value
	N = 1207	N = 1171
Metastasis-free survival
PROSPER definition (112-day cutoff)c	0.27 (0.22; 0.33), p < 0.001	0.26 (0.21; 0.33), p < 0.001
SPARTAN definition	0.28 (0.23; 0.35), p < 0.001d	0.28 (0.23; 0.35), p < 0.001
Overall survival	0.70 (0.47; 1.04), p = 0.07d	0.62 (0.41; 0.94), p = 0.024

HR hazard ratio, CI confidence interval, MAIC matching-adjusted indirect comparison

^aSPARTAN patients were stratified according to PSA doubling time (> 6 months vs. ≤ 6 months), use of bone-targeting agents (yes vs. no), and classification of local or regional nodal disease (N0 vs. N1) at the time of study entry. Efficacy analyses were performed using a log-rank test

^bSPARTAN patients were matched to PROSPER patients on the following variables: age, PSA and PSA doubling time at baseline, Eastern Cooperative Oncology Group performance status, total Gleason score, use of bone-targeting agents, and history of surgical prostate cancer procedures at baseline

^cFor this analysis, any events occurring after 112 days after treatment discontinuation were censored

^dResults reported in the SPARTAN study [6]